Prof. Matthew Groves from the Groningen Research Institute of Pharmacy (GRIP) is partner in a consortium that has been awarded a H2020 Marie Curie ETN grant. The grant of EUR 3.2 million is for the MepAnti project, which aims to tackle the antimicrobial resistance problem by targeting enzymes of the methylerythritol phosphate pathway.
Antimicrobial resistance is a serious global health problem and, at present, there is no inter-institutional and interdisciplinary consortium explicitly focused on the discovery and development of novel anti-infective agents. The MepAnti consortium consists of nine academic partners and seven non-academic partners. The Helmholtz Institute for Pharmaceutical Research Saarland is coordinator. The consortium aims to go beyond the state-of-the-art in the anti-infective field by tackling the attractive and underexplored enzymes from the 2C-methyl-D-erythritol 4-phosphate (MEP) pathway.
Prof. Groves receives EUR 265,000 for his part in the project. He will provide structural biology and biophysical expertise, with a focus on the first and rate-limiting step catalyzed by DXS.
The cross-disciplinary team receives the award for the development of ‘Comparative Lipidomics, a new strategy to study pathogenic bacteria that forms the basis for novel drug development, diagnostics and vaccines’.
He focused on the importance of habitat quality for nursery fish.
Winning a gold medal means that the team has performed exceptionally well with their project.